PATENT CLAIM ANALYSIS

Application Number: 16058303
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "383000"]

Abstract:
The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R 1  is a 5- to 6-membered ring group which may be substituted; X 1  is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X 2  is a bivalent group of 1 to 4 atoms; Z 1  is a bivalent cyclic ring group or the like; Z 2  is a bond or the like; and R 2  is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Claim (Index 67):
The method of  claim 66 , wherein the second compound is a nucleic acid reverse transcriptase inhibitor selected from the group consisting of zidovudine, didanosine, zalcitabine, lamivudine, stavudine, abacavir, adefovir, adefovir dipivoxil, and fozivudine tidoxil.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 2.59649
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14261683', '11978198', '12119355', '13476454', '10484762']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8430716071916035
- 35 USC 102 Novelty (BERT): 0.5669814069988967
- Combined Prediction Score: 0.8154625871723328
- Mean Citation Score: 479.520306
- Max Citation Score: 512.11743
- Similarity Product: 317.98593999319195

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test